Myriad Genetics to Unveil 2025 Earnings and New Cancer Diagnostics on February 23

Myriad Genetics, a leader in genetic testing and precision medicine, will release its fourth quarter and full year 2025 earnings on February 23, 2026. The company specialises in tests that assess disease risk and guide treatment decisions, with plans to expand its cancer diagnostics portfolio in the coming year.

The earnings report will be published after the market closes on February 23, 2026. A conference call for investors and analysts is scheduled for 4:30 pm ET the same day. A live webcast will be available on Myriad's Investor Relations website.

During the call, the company is not expected to share specific financial or operational targets for fiscal year 2025. Instead, focus will likely remain on upcoming product launches. Precise MRD™ for breast cancer will roll out in March 2026, initially with selected physicians. Tests for colorectal and kidney cancers are planned for later in 2026, with potential expansion to ovarian and endometrial cancers from 2027.

Myriad's leadership will also attend key industry events in March. CEO Sam Raha and CFO Ben Wheeler will participate in the TD Cowen 46th Annual Health Care Conference on March 3. The company will then join the Leerink Partners Global Healthcare Conference on March 10.

Analysts currently estimate earnings per share of $0.01 for 2025. The company's near-term priorities include launching new cancer diagnostics and engaging with investors at major healthcare conferences. No further financial guidance for 2025 has been provided at this time.